Skip to main content
Top
Published in: Medical Microbiology and Immunology 4/2020

Open Access 01-08-2020 | Insulins | Review

Autoimmunity to tetraspanin-7 in type 1 diabetes

Authors: Kerry A. McLaughlin, Melissa A. Tombs, Michael R. Christie

Published in: Medical Microbiology and Immunology | Issue 4/2020

Login to get access

Abstract

Type 1 diabetes is an autoimmune disease whereby components of insulin-secreting pancreatic beta cells are targeted by the adaptive immune system leading to the destruction of these cells and insulin deficiency. There is much interest in the development of antigen-specific immune intervention as an approach to prevent disease development in individuals identified as being at risk of disease. It is now recognised that there are multiple targets of the autoimmune response in type 1 diabetes, the most recently identified being a member of the tetraspanin family, tetraspanin-7. The heterogeneity of autoimmune responses to different target antigens complicates the assessment of diabetes risk by the detection of autoantibodies, as well as creating challenges for the design of strategies to intervene in the immune response to these autoantigens. This review describes the discovery of tetraspanin-7 as a target of autoantibodies in type 1 diabetes and how the detection of autoantibodies to the protein provides a valuable marker for future loss of pancreatic beta-cell function.
Literature
1.
2.
go back to reference Noble JA (2015) Immunogenetics of type 1 diabetes: a comprehensive review. J Autoimmun 64:101–112PubMedCrossRef Noble JA (2015) Immunogenetics of type 1 diabetes: a comprehensive review. J Autoimmun 64:101–112PubMedCrossRef
3.
go back to reference Gorsuch AN, Spencer KM, Lister J, McNally JM, Dean BM, Bottazzo GF, Cudworth AG (1981) Evidence for a long prediabetic period in Type 1 (insulin-dependent) diabetes mellitus. Lancet II:1363–1365CrossRef Gorsuch AN, Spencer KM, Lister J, McNally JM, Dean BM, Bottazzo GF, Cudworth AG (1981) Evidence for a long prediabetic period in Type 1 (insulin-dependent) diabetes mellitus. Lancet II:1363–1365CrossRef
4.
5.
go back to reference Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361:2143–2152PubMedPubMedCentralCrossRef Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361:2143–2152PubMedPubMedCentralCrossRef
6.
go back to reference Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA (2002) Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N Engl J Med 346:1692–1698PubMedCrossRef Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA (2002) Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N Engl J Med 346:1692–1698PubMedCrossRef
7.
go back to reference Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381:603–613PubMedPubMedCentralCrossRef Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381:603–613PubMedPubMedCentralCrossRef
8.
go back to reference McLaughlin KA, Richardson CC, Ravishankar A, Brigatti C, Liberati D, Lampasona V, Piemonti L, Morgan D, Feltbower RG, Christie MR (2016) Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes. Diabetes 65:1690–1698PubMedCrossRef McLaughlin KA, Richardson CC, Ravishankar A, Brigatti C, Liberati D, Lampasona V, Piemonti L, Morgan D, Feltbower RG, Christie MR (2016) Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes. Diabetes 65:1690–1698PubMedCrossRef
9.
go back to reference Baekkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, Lernmark A (1982) Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 298:167–169PubMedCrossRef Baekkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, Lernmark A (1982) Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 298:167–169PubMedCrossRef
10.
go back to reference Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P (1990) Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347:151–156PubMedCrossRef Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P (1990) Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347:151–156PubMedCrossRef
11.
go back to reference Payton MA, Hawkes CJ, Christie MR (1995) Relationship of the 37,000 and 40,000 Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 96:1506–1511PubMedPubMedCentralCrossRef Payton MA, Hawkes CJ, Christie MR (1995) Relationship of the 37,000 and 40,000 Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 96:1506–1511PubMedPubMedCentralCrossRef
12.
go back to reference Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL (1983) Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222:1337–1339PubMedCrossRef Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL (1983) Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222:1337–1339PubMedCrossRef
13.
go back to reference Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci 104:17040–17045PubMedPubMedCentralCrossRef Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci 104:17040–17045PubMedPubMedCentralCrossRef
14.
go back to reference Roll U, Christie MR, Fuchtenbusch M, Payton MA, Hawkes CJ, Ziegler AG (1996) Perinatal autoimmunity in offspring of diabetic parents: the German multicentre ‘BABY-DIAB’ study. Detection of humoral immune responses to islet antigens in early childhood. Diabetes 45:967–973PubMedCrossRef Roll U, Christie MR, Fuchtenbusch M, Payton MA, Hawkes CJ, Ziegler AG (1996) Perinatal autoimmunity in offspring of diabetic parents: the German multicentre ‘BABY-DIAB’ study. Detection of humoral immune responses to islet antigens in early childhood. Diabetes 45:967–973PubMedCrossRef
15.
go back to reference Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef
16.
go back to reference Ziegler AG, Bonifacio E, BABYDIAB-BABYDIET Study Group (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 5:1937–1943CrossRef Ziegler AG, Bonifacio E, BABYDIAB-BABYDIET Study Group (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 5:1937–1943CrossRef
17.
go back to reference Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, Eisenbarth GS, Rewers M (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab 89:3896–3902PubMedCrossRef Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, Eisenbarth GS, Rewers M (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab 89:3896–3902PubMedCrossRef
18.
go back to reference Long AE, Wilson IV, Becker DJ, Libman IM, Arena VC, Wong FS, Steck AK, Rewers MJ, Yu L, Achenbach P, Casas R, Ludvigsson J, Williams AJK, Gillespie KM (2018) Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. Diabetologia 61:1484–1490PubMedPubMedCentralCrossRef Long AE, Wilson IV, Becker DJ, Libman IM, Arena VC, Wong FS, Steck AK, Rewers MJ, Yu L, Achenbach P, Casas R, Ludvigsson J, Williams AJK, Gillespie KM (2018) Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. Diabetologia 61:1484–1490PubMedPubMedCentralCrossRef
19.
go back to reference Bingley PJ, Christie MR, Bonifacio E, Bonifanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA (1994) Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43:1304–1310PubMedCrossRef Bingley PJ, Christie MR, Bonifacio E, Bonifanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA (1994) Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43:1304–1310PubMedCrossRef
20.
go back to reference Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase HP, Eisenbarth GS (1996) Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 9:379–383PubMedCrossRef Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase HP, Eisenbarth GS (1996) Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 9:379–383PubMedCrossRef
21.
go back to reference Christie MR, Roll U, Payton MA, Hatfield ECI, Ziegler AG (1997) Validity of screening for individuals at risk for Type 1 diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care 20:965–970PubMedCrossRef Christie MR, Roll U, Payton MA, Hatfield ECI, Ziegler AG (1997) Validity of screening for individuals at risk for Type 1 diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care 20:965–970PubMedCrossRef
22.
go back to reference Aanstoot HJ, Kang SM, Kim J, Lindsay LA, Roll U, Knip M, Atkinson M, Mose-Larsen P, Fey S, Ludvigsson J, Landin L, Bruining J, Maclaren N, Akerblom HK, Baekkeskov S (1996) Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. J Clin Invest 97:2772–2783PubMedPubMedCentralCrossRef Aanstoot HJ, Kang SM, Kim J, Lindsay LA, Roll U, Knip M, Atkinson M, Mose-Larsen P, Fey S, Ludvigsson J, Landin L, Bruining J, Maclaren N, Akerblom HK, Baekkeskov S (1996) Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. J Clin Invest 97:2772–2783PubMedPubMedCentralCrossRef
23.
go back to reference Bordier C (1981) Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 256:1604–1607PubMedCrossRef Bordier C (1981) Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 256:1604–1607PubMedCrossRef
24.
go back to reference Roll U, Turck CW, Gitelman SE, Rosenthal SM, Nolte MS, Masharani U, Ziegler AG, Baekkeskov S (2000) Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients. Diabetologia 43:598–608PubMedCrossRef Roll U, Turck CW, Gitelman SE, Rosenthal SM, Nolte MS, Masharani U, Ziegler AG, Baekkeskov S (2000) Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients. Diabetologia 43:598–608PubMedCrossRef
25.
go back to reference Perot BP, Ménager MM (2020) Tetraspanin 7 and its paralog tetraspanin 6: membrane organizers with key functions in brain development, viral infection, innate immunity, diabetes and cancer. Med Microbiol Immun: In Press Perot BP, Ménager MM (2020) Tetraspanin 7 and its paralog tetraspanin 6: membrane organizers with key functions in brain development, viral infection, innate immunity, diabetes and cancer. Med Microbiol Immun: In Press
26.
go back to reference Lee SA, Suh Y, Lee S, Jeong J, Kim SJ, Kim SJ, Park SK (2017) Functional expression of dopamine D2 receptor is regulated by tetraspanin 7-mediated postendocytic trafficking. FASEB J 31:2301–2313PubMedCrossRef Lee SA, Suh Y, Lee S, Jeong J, Kim SJ, Kim SJ, Park SK (2017) Functional expression of dopamine D2 receptor is regulated by tetraspanin 7-mediated postendocytic trafficking. FASEB J 31:2301–2313PubMedCrossRef
27.
go back to reference Bassani S, Cingolani LA, Valnegri P, Folci A, Zapata J, Gianfelice A, Sala C, Goda Y, Passafaro M (2012) The X-linked intellectual disability protein TSPAN7 regulates excitatory synapse development and AMPAR trafficking. Neuron 73:1143–1158PubMedPubMedCentralCrossRef Bassani S, Cingolani LA, Valnegri P, Folci A, Zapata J, Gianfelice A, Sala C, Goda Y, Passafaro M (2012) The X-linked intellectual disability protein TSPAN7 regulates excitatory synapse development and AMPAR trafficking. Neuron 73:1143–1158PubMedPubMedCentralCrossRef
28.
go back to reference Yauch RL, Hemler ME (2000) Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase. Biochem J 351:629–637PubMedPubMedCentralCrossRef Yauch RL, Hemler ME (2000) Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase. Biochem J 351:629–637PubMedPubMedCentralCrossRef
29.
go back to reference Guo M, Huang T, Cui Y, Pan B, Shen A, Sun Y, Yi Y, Wang Y, Xiao G, Sun G (2008) PrPC interacts with tetraspanin-7 through bovine PrP154-182 containing alpha-helix 1. Biochem Biophys Res Commun 365:154–157PubMedCrossRef Guo M, Huang T, Cui Y, Pan B, Shen A, Sun Y, Yi Y, Wang Y, Xiao G, Sun G (2008) PrPC interacts with tetraspanin-7 through bovine PrP154-182 containing alpha-helix 1. Biochem Biophys Res Commun 365:154–157PubMedCrossRef
30.
go back to reference Zemni R, Bienvenu T, Vinet MC, Sefiani A, Carrie A, Billuart P, McDonell N, Couvert P, Francis F, Chafey P et al (2000) A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation. Nat Genet 24:167–170PubMedCrossRef Zemni R, Bienvenu T, Vinet MC, Sefiani A, Carrie A, Billuart P, McDonell N, Couvert P, Francis F, Chafey P et al (2000) A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation. Nat Genet 24:167–170PubMedCrossRef
32.
33.
go back to reference Achenbach P, Schlosser M, Williams AJ, Yu L, Mueller PW, Bingley PJ, Bonifacio E (2007) Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol 122:85–90PubMedCrossRef Achenbach P, Schlosser M, Williams AJ, Yu L, Mueller PW, Bingley PJ, Bonifacio E (2007) Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol 122:85–90PubMedCrossRef
34.
go back to reference Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Laboratories P (2008) Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen. Diabetologia 51:846–852PubMedCrossRef Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Laboratories P (2008) Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen. Diabetologia 51:846–852PubMedCrossRef
35.
go back to reference Lampasona V, Schlosser M, Mueller PW, Williams AJ, Wenzlau JM, Hutton JC, Achenbach P (2011) Diabetes Antibody Standardization Program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 57:1693–1702PubMedCrossRef Lampasona V, Schlosser M, Mueller PW, Williams AJ, Wenzlau JM, Hutton JC, Achenbach P (2011) Diabetes Antibody Standardization Program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 57:1693–1702PubMedCrossRef
36.
go back to reference Lampasona V, Pittman DL, Williams AJ, Achenbach P, Schlosser M, Akolkar B, Winter WE, Laboratories P (2019) Islet Autoantibody Standardization Program 2018 workshop: interlaboratory comparison of glutamic acid decarboxylase autoantibody assay performance. Clin Chem 65:1141–1152PubMedPubMedCentralCrossRef Lampasona V, Pittman DL, Williams AJ, Achenbach P, Schlosser M, Akolkar B, Winter WE, Laboratories P (2019) Islet Autoantibody Standardization Program 2018 workshop: interlaboratory comparison of glutamic acid decarboxylase autoantibody assay performance. Clin Chem 65:1141–1152PubMedPubMedCentralCrossRef
37.
go back to reference Walther D, Eugster A, Jergens S, Gavrisan A, Weinzierl C, Telieps T, Winkler C, Ziegler AG, Bonifacio E (2016) Tetraspanin 7 autoantibodies in type 1 diabetes. Diabetologia 59:1973–1976PubMedCrossRef Walther D, Eugster A, Jergens S, Gavrisan A, Weinzierl C, Telieps T, Winkler C, Ziegler AG, Bonifacio E (2016) Tetraspanin 7 autoantibodies in type 1 diabetes. Diabetologia 59:1973–1976PubMedCrossRef
38.
go back to reference Myers MA, Davies JM, Tong JC, Whisstock J, Scealy M, Mackay IR, Rowley MJ (2000) Conformational epitopes on the diabetes autoantigen GAD65 identified by peptide phage display and molecular modeling. J Immunol 165:3830–3838PubMedCrossRef Myers MA, Davies JM, Tong JC, Whisstock J, Scealy M, Mackay IR, Rowley MJ (2000) Conformational epitopes on the diabetes autoantigen GAD65 identified by peptide phage display and molecular modeling. J Immunol 165:3830–3838PubMedCrossRef
39.
go back to reference Dromey JA, Weenink SM, Peters GH, Endl J, Tighe PJ, Todd I, Christie MR (2004) Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J Immunol 172:4084–4090PubMedCrossRef Dromey JA, Weenink SM, Peters GH, Endl J, Tighe PJ, Todd I, Christie MR (2004) Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J Immunol 172:4084–4090PubMedCrossRef
40.
go back to reference McLaughlin KA, Richardson CC, Williams S, Bonifacio E, Morgan D, Feltbower RG, Powell M, Rees Smith B, Furmaniak J, Christie MR (2015) Relationships between major epitopes of the IA-2 autoantigen in type 1 diabetes: implications for determinant spreading. Clin Immunol 160:226–236PubMedCrossRef McLaughlin KA, Richardson CC, Williams S, Bonifacio E, Morgan D, Feltbower RG, Powell M, Rees Smith B, Furmaniak J, Christie MR (2015) Relationships between major epitopes of the IA-2 autoantigen in type 1 diabetes: implications for determinant spreading. Clin Immunol 160:226–236PubMedCrossRef
41.
go back to reference Burbelo PD, Lebovitz EE, Notkins AL (2015) Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl Res 165:325–335PubMedCrossRef Burbelo PD, Lebovitz EE, Notkins AL (2015) Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl Res 165:325–335PubMedCrossRef
42.
go back to reference Charrin S, Manié S, Thiele C, Billard M, Gerlier D, Boucheix C, Rubinstein E (2003) A physical and functional link between cholesterol and tetraspanins. Eur J Immunol 33:2479–2489PubMedCrossRef Charrin S, Manié S, Thiele C, Billard M, Gerlier D, Boucheix C, Rubinstein E (2003) A physical and functional link between cholesterol and tetraspanins. Eur J Immunol 33:2479–2489PubMedCrossRef
43.
go back to reference Zimmerman B, Kelly B, McMillan BJ, Seegar TCM, Dror RO, Kruse AC, Blacklow SC (2016) Crystal structure of a full-length human tetraspanin reveals a cholesterol-binding pocket. Cell 167:1041–1051PubMedPubMedCentralCrossRef Zimmerman B, Kelly B, McMillan BJ, Seegar TCM, Dror RO, Kruse AC, Blacklow SC (2016) Crystal structure of a full-length human tetraspanin reveals a cholesterol-binding pocket. Cell 167:1041–1051PubMedPubMedCentralCrossRef
44.
go back to reference Mclaughlin KA, Liberati D, Lampasona V, Feltbower R, Christie MR (2018) Autoantibody reactivity to tetraspanin-7 is directed to the cytoplasmic domains: Implications for immunoassay design. Diabet Med 35:67 Mclaughlin KA, Liberati D, Lampasona V, Feltbower R, Christie MR (2018) Autoantibody reactivity to tetraspanin-7 is directed to the cytoplasmic domains: Implications for immunoassay design. Diabet Med 35:67
45.
go back to reference Eugster A, Kraus G, Lidzba V, Müller D, Jolink M, Ziegler AG, Bonifacio E (2019) Cytoplasmic ends of tetraspanin 7 harbour epitopes recognised by autoantibodies in type 1 diabetes. Diabetologia 62:805–810PubMedCrossRef Eugster A, Kraus G, Lidzba V, Müller D, Jolink M, Ziegler AG, Bonifacio E (2019) Cytoplasmic ends of tetraspanin 7 harbour epitopes recognised by autoantibodies in type 1 diabetes. Diabetologia 62:805–810PubMedCrossRef
46.
go back to reference Winnock F, Christie MR, Batstra MR, Aanstoot H-J, Weets I, Decochez K, Jopart P, Nicolaij D, Gorus FK, the Belgian Diabetes Registry (2001) Autoantibodies to a 38 kDa glycosylated islet cell membrane- associated antigen in (pre)type 1 diabetes : association with IA-2 and islet cell autoantibodies. Diabetes Care 24:1181–1186PubMedCrossRef Winnock F, Christie MR, Batstra MR, Aanstoot H-J, Weets I, Decochez K, Jopart P, Nicolaij D, Gorus FK, the Belgian Diabetes Registry (2001) Autoantibodies to a 38 kDa glycosylated islet cell membrane- associated antigen in (pre)type 1 diabetes : association with IA-2 and islet cell autoantibodies. Diabetes Care 24:1181–1186PubMedCrossRef
47.
go back to reference Groom O, McLaughlin K, Johns J, Walkey H, Kaur A, Williams A, Godsland I, Oliver N, Johnston D, Misra S (2019) Utility of anti-tetraspanin 7 auto-antibodies in adults and children with type 1 diabetes: insights from the ADDRESS-2 study. Diabetologia 62:S204–S205 Groom O, McLaughlin K, Johns J, Walkey H, Kaur A, Williams A, Godsland I, Oliver N, Johnston D, Misra S (2019) Utility of anti-tetraspanin 7 auto-antibodies in adults and children with type 1 diabetes: insights from the ADDRESS-2 study. Diabetologia 62:S204–S205
48.
go back to reference Shi X, Huang G, Wang Y, Liu Z, Deng C, Li X, Zheng P, Zhou Z (2019) Tetraspanin 7 autoantibodies predict progressive decline of beta cell function in individuals with LADA. Diabetologia 62:399–407PubMedCrossRef Shi X, Huang G, Wang Y, Liu Z, Deng C, Li X, Zheng P, Zhou Z (2019) Tetraspanin 7 autoantibodies predict progressive decline of beta cell function in individuals with LADA. Diabetologia 62:399–407PubMedCrossRef
49.
go back to reference Silveira PA, Grey ST (2006) B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol Metab 17:128–135PubMedCrossRef Silveira PA, Grey ST (2006) B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol Metab 17:128–135PubMedCrossRef
50.
go back to reference Solimena M, De Camilli P (1991) Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 14:452–457PubMedCrossRef Solimena M, De Camilli P (1991) Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 14:452–457PubMedCrossRef
51.
go back to reference Christie MR, Genovese S, Cassidy D, Bosi E, Brown TJ, Gale EAM, Bonifacio E, Bottazzo GF (1994) Antibodies to islet 37k-antigen, but not to glutamate decarboxylase, discriminate rapid progression to insulin-dependent diabetes mellitus in endocrine autoimmunity. Diabetes 43:1254–1259PubMedCrossRef Christie MR, Genovese S, Cassidy D, Bosi E, Brown TJ, Gale EAM, Bonifacio E, Bottazzo GF (1994) Antibodies to islet 37k-antigen, but not to glutamate decarboxylase, discriminate rapid progression to insulin-dependent diabetes mellitus in endocrine autoimmunity. Diabetes 43:1254–1259PubMedCrossRef
52.
go back to reference Thurner L, Müller A, Cérutti M, Martin T, Pasquali JL, Gross WL, Preuss KD, Pfreundschuh M, Voswinkel J (2011) Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin. J Autoimmun 36:87–90PubMedCrossRef Thurner L, Müller A, Cérutti M, Martin T, Pasquali JL, Gross WL, Preuss KD, Pfreundschuh M, Voswinkel J (2011) Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin. J Autoimmun 36:87–90PubMedCrossRef
53.
go back to reference Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, Davis JC, Ytterberg SR, St Clair EW, McCune WJ, Specks U, Allen NB, Luqmani RA, Stone JH, WGET Research Group (2005) Damage caused by Wegener’s granulomatosis and its treatment: Prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52:2168–2178PubMedCrossRef Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, Davis JC, Ytterberg SR, St Clair EW, McCune WJ, Specks U, Allen NB, Luqmani RA, Stone JH, WGET Research Group (2005) Damage caused by Wegener’s granulomatosis and its treatment: Prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52:2168–2178PubMedCrossRef
54.
go back to reference Hemminki K, Li X, Sundquist J, Sundquist K (2009) Familial association between type 1 diabetes and other autoimmune and related diseases. Diabetologia 52:1820–1828PubMedCrossRef Hemminki K, Li X, Sundquist J, Sundquist K (2009) Familial association between type 1 diabetes and other autoimmune and related diseases. Diabetologia 52:1820–1828PubMedCrossRef
55.
go back to reference McLaughlin KA, Gulati K, Richardson CC, Morgan D, Bodansky HJ, Feltbower RG, Christie MR (2014) HLA-DR4-associated T and B cell responses to specific determinants on the IA-2 autoantigen in type 1 diabetes. J Immunol 193:4448–4456PubMedCrossRef McLaughlin KA, Gulati K, Richardson CC, Morgan D, Bodansky HJ, Feltbower RG, Christie MR (2014) HLA-DR4-associated T and B cell responses to specific determinants on the IA-2 autoantigen in type 1 diabetes. J Immunol 193:4448–4456PubMedCrossRef
56.
Metadata
Title
Autoimmunity to tetraspanin-7 in type 1 diabetes
Authors
Kerry A. McLaughlin
Melissa A. Tombs
Michael R. Christie
Publication date
01-08-2020
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 4/2020
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-020-00674-2

Other articles of this Issue 4/2020

Medical Microbiology and Immunology 4/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.